Last reviewed · How we verify
GLPG3067 oral suspension
GLPG3067 oral suspension is a Small molecule drug developed by Galapagos NV. It is currently in Phase 1 development.
At a glance
| Generic name | GLPG3067 oral suspension |
|---|---|
| Sponsor | Galapagos NV |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLPG3067 oral suspension CI brief — competitive landscape report
- GLPG3067 oral suspension updates RSS · CI watch RSS
- Galapagos NV portfolio CI
Frequently asked questions about GLPG3067 oral suspension
What is GLPG3067 oral suspension?
GLPG3067 oral suspension is a Small molecule drug developed by Galapagos NV.
Who makes GLPG3067 oral suspension?
GLPG3067 oral suspension is developed by Galapagos NV (see full Galapagos NV pipeline at /company/galapagos-nv).
What development phase is GLPG3067 oral suspension in?
GLPG3067 oral suspension is in Phase 1.
Related
- Manufacturer: Galapagos NV — full pipeline
- Compare: GLPG3067 oral suspension vs similar drugs
- Pricing: GLPG3067 oral suspension cost, discount & access